Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM

Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m(2)/wee...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Jaeckle, Kurt A., Ballman, Karla V., Giannini, Caterina, Schomberg, Paula J., Ames, Matthew M., Reid, Joel M., McGovern, Renee M., Safgren, Stephanie L., Galanis, Evanthia, Uhm, Joon H., Brown, Paul D., Hammack, Julie E., Arusell, Robert, Nikcevich, Daniel A., Morton, Roscoe F., Wender, Donald B., Buckner, Jan C.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2010
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897141/
https://ncbi.nlm.nih.gov/pubmed/20063115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-009-0103-2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items